UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years

Journal of rheumatology, 2015-10, Vol.42 (10), p.1761-1766

2015

Volltextzugriff (PDF)

A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis

Arthritis research & therapy, 2018-08, Vol.20 (1), p.178-178, Article 178

2018

Volltextzugriff (PDF)

Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial

Arthritis research & therapy, 2021-09, Vol.23 (1), p.1-248, Article 248

2021

Volltextzugriff (PDF)

Safety of Biologic Therapy in Rheumatoid Arthritis and Other Autoimmune Diseases: Focus on Rituximab

Seminars in arthritis and rheumatism, 2009-02, Vol.38 (4), p.265-280

Fleischmann, Roy M., MD

2009

Volltextzugriff (PDF)

A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis

The New England journal of medicine, 2000-11, Vol.343 (22), p.1586-1593

2000

Volltextzugriff (PDF)

Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)

Journal of rheumatology, 2003-12, Vol.30 (12), p.2563

2003

Volltextzugriff (PDF)

EULAR PsA management recommendations 2019: can the recommendations be improved?

Annals of the rheumatic diseases, 2020-06, Vol.79 (6), p.700-712

Fleischmann, Roy M

2020

Volltextzugriff (PDF)

Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response

Annals of the rheumatic diseases, 2019-11, Vol.78 (11), p.1454-1462

2019

Volltextzugriff (PDF)

A Phase II Trial of Lutikizumab, an Anti–Interleukin‐1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis

Arthritis & rheumatology (Hoboken, N.J.), 2019-07, Vol.71 (7), p.1056-1069

2019

Volltextzugriff (PDF)

Jack pot! What can we learn about registries with respect to treatment cycling in rheumatoid arthritis?

Annals of the rheumatic diseases, 2023-02, Vol.82 (2), p.161-163

2023

Volltextzugriff (PDF)

Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study

Annals of the rheumatic diseases, 2013-01, Vol.72 (1), p.64-71

2013

Volltextzugriff (PDF)

Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis

Journal of rheumatology, 2006-02, Vol.33 (2), p.234

2006

Volltextzugriff (PDF)

A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial

Journal of rheumatology, 2016-09, Vol.43 (9), p.1724-1734

2016

Volltextzugriff (PDF)

Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients

Annals of the rheumatic diseases, 2013-09, Vol.72 (9), p.1496-1502

2013

Volltextzugriff (PDF)

Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis

Annals of the rheumatic diseases, 2019-03, Vol.78 (3), p.413-420

2019

Volltextzugriff (PDF)

Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study

Annals of the rheumatic diseases, 2022-12, Vol.81 (12), p.1661-1668

2022

Volltextzugriff (PDF)

Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment

Annals of the rheumatic diseases, 2024-07, p.ard-2023-225473

2024

Volltextzugriff (PDF)

Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis

The New England journal of medicine, 2022-08, Vol.387 (8), p.715-726

2022

Volltextzugriff (PDF)

Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial

Annals of the rheumatic diseases, 2015-06, Vol.74 (6), p.1037-1044

2015

Volltextzugriff (PDF)

A Randomized, Double‐Blind, Placebo‐Controlled, Twelve‐Week, Dose‐Ranging Study of Decernotinib, an Oral Selective JAK‐3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis

Arthritis & rheumatology (Hoboken, N.J.), 2015-02, Vol.67 (2), p.334-343

2015

Volltextzugriff (PDF)

Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis

Journal of rheumatology, 2005-07, Vol.32 (7), p.1232

2005

Volltextzugriff (PDF)

Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial

Annals of the rheumatic diseases, 2014-09, Vol.73 (9), p.1626-1634

2014

Volltextzugriff (PDF)

Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1)

Rheumatology, 2020-10, Vol.59 (10), p.2774-2784

2020

Volltextzugriff (PDF)

Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results

Journal of rheumatology, 2013-02, Vol.40 (2), p.113-126

2013

Volltextzugriff (PDF)

1 – 25 von 149

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(130)
Mit Volltextzugriff
(105)

Publikationsform

Artikel
(149)

Sprache

Englisch
(149)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(120)
Science & Technology
(120)
Humans
(102)
Rheumatology
(96)
Female
(83)
Male
(82)
Middle Aged
(82)
Arthritis, Rheumatoid - Drug Therapy
(76)
Rheumatoid Arthritis
(73)
Treatment Outcome
(65)
Adult
(54)
Antirheumatic Agents - Therapeutic Use
(53)
Double-Blind Method
(53)
Biological And Medical Sciences
(46)
Medical Sciences
(46)
Aged
(42)
Drug Therapy, Combination
(39)
Antirheumatic Agents - Adverse Effects
(37)
Pharmacology. Drug Treatments
(36)
Antirheumatic Agents - Administration & Dosage
(30)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years

A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis

Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial

Safety of Biologic Therapy in Rheumatoid Arthritis and Other Autoimmune Diseases: Focus on Rituximab

A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis

Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)

EULAR PsA management recommendations 2019: can the recommendations be improved?

Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response

A Phase II Trial of Lutikizumab, an Anti–Interleukin‐1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis

Jack pot! What can we learn about registries with respect to treatment cycling in rheumatoid arthritis?

Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement

Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study

Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis

A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial

Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients

Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis

Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study

Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment

Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis

Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial

A Randomized, Double‐Blind, Placebo‐Controlled, Twelve‐Week, Dose‐Ranging Study of Decernotinib, an Oral Selective JAK‐3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis

Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis

Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial

Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1)

Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results

Suchergebnisse filtern